Multidrug-Resistant Tuberculosis Drugs
The included case reports were most numerous for bedaquiline and least numerous for pretomanid. The study evaluated real-world adverse event reports for bedaquiline, delamanid, and pretomanid using FAERS data from 2015 through 2023. A posi…
1 sources - 5 claims
The included case reports were most numerous for bedaquiline and least numerous for pretomanid. The study evaluated real-world adverse event reports for bedaquiline, delamanid, and pretomanid using FAERS data from 2015 through 2023. A positive adverse event signal required confirmation by all four disproportionality algorithms. All three drugs were associated with serious adverse event outcomes in more than half of reported outcomes. Bedaquiline, delamanid, and pretomanid are central novel agents in current MDR-TB therapy.